There has been an exponential growth in the pursuits of better targeted therapy to optimize IBD clinical outcomes. IBD therapies that explore new targets and inflammatory pathways are emerging to address the current treatment gaps observed with conventional and biologic therapies.
Dr. Mike JonesTargeted Therapy
Differentiate between disease activity and disease severity to drive treatment decisions in patients with UC.
Apply the unique risk/benefit profiles of different biologic therapies when making treatment decisions based on individual prognosis and severity of disease.
Utilize data from real-world studies on the use and effectiveness of biologic therapy for UC to initiate early, effective treatment for patients with UC.